Dexcom, Inc.

Company

Also known as: Dexcom

Related News

Diabetes Tech Companies Launch Enhanced CGM Systems and Insulin Delivery Platforms

Jun 04, 2026

Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.

CGM study and coverage push highlight broader use in Type 2 diabetes

Apr 26, 2026

A UK trial found continuous glucose monitoring improved HbA1c and time in range for adults with type 2 diabetes using basal insulin. Dexcom is also awaiting a Medicare decision on broader CGM coverage for non-insulin users.

DexCom reports higher 2025 sales and reaffirms 2026 revenue outlook

Apr 12, 2026

DexCom reported fourth-quarter 2025 revenue of US$1.26 billion and net income of US$267.3 million, with full-year sales of US$4.66 billion. The company reaffirmed 2026 revenue guidance of US$5.16–US$5.25 billion and targeted a non-GAAP operating margin of about 22–23%.